Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.
The following table provides information about the project.
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA
|Coordinator Country||Spain [ES]|
|Total cost||3˙993˙056 €|
|EC max contribution||3˙577˙431 € (90%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2022-12-31|
Take a look of project's partnership.
|1||FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA||ES (VALENCIA)||coordinator||638˙315.00|
|2||IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP||PT (PORTO)||participant||660˙162.00|
|3||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||participant||550˙000.00|
|4||STICHTING VUMC||NL (AMSTERDAM)||participant||471˙875.00|
|5||PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE||CL (SANTIAGO)||participant||305˙235.00|
|6||ANAXOMICS BIOTECH, S.L.||ES (BARCELONA)||participant||275˙218.00|
|7||CABALLERO LLANO CARMELO CESAR||PY (ASUNCION)||participant||216˙093.00|
|8||EUROPEAN CANCER PATIENT COALITION||BE (BRUXELLES)||participant||197˙750.00|
|9||ALEXANDER FLEMING SA||AR (BUENOS AIRES)||participant||131˙625.00|
|10||UNIVERSITAET LEIPZIG||DE (LEIPZIG)||participant||131˙156.00|
|11||Instituto Nacional de Cancerología||MX (MEXICO)||participant||0.00|
Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More